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Abstract: In the Wuhan Province of China, in December 2019, the novel coronavirus 2019 (COVID-19) has caused a severe involvement
of the lower respiratory tract leading to an acute respiratory syndrome. Subsequently, coronavirus 2 (SARS-CoV-2) provoked a
pandemic which is considered a life-threatening disease. The SARS-CoV-2, a family member of betacoronaviruses, possesses singlestranded positive-sense RNA with typical structural proteins, involving the envelope, membrane, nucleocapsid and spike proteins
that are responsible for the viral infectivity, and nonstructural proteins. The effectual host immune response including innate and
adaptive immunity against SARS-Cov-2 seems crucial to control and resolve the viral infection. However, the severity and outcome
of the COVID-19 might be associated with the excessive production of proinflammatory cytokines “cytokine storm” leading to an
acute respiratory distress syndrome. Regretfully, the exact pathophysiology and treatment, especially for the severe COVID-19, is
still uncertain. The results of preliminary studies have shown that immune-modulatory or immune-suppressive treatments such as
hydroxychloroquine, interleukin (IL)-6 and IL-1 antagonists, commonly used in rheumatology, might be considered as treatment
choices for COVID-19, particularly in severe disease. In this review, to gain better information about appropriate anti-inflammatory
treatments, mostly used in rheumatology for COVID-19, we have focused the attention on the structural features of SARS-CoV-2, the
host immune response against SARS-CoV-2 and its association with the cytokine storm.
Keywords: COVID-19, inflammation, cytokine storm, antiinflammatory, treatment, rheumatology

1. Introduction
Coronaviruses (CoVs), mainly targeting human
respiratory system, are responsible for health-threatening
outbreaks including severe acute respiratory syndrome
(SARS), Middle East respiratory syndrome (MERS)
and lastly coronavirus disease 2019 (COVID-19) [1]. In
December 2019, in the Chinese Province of Wuhan the
novel coronavirus has been identified in patients with
atypical pneumonia characterized by fever, dry cough and
progressive dyspnea [2]. Rapidly, this coronavirus, namely
SARS-CoV-21, has spread worldwide, leading to a serious
lung inflammation, acute respiratory distress syndrome
(ARDS), cardiac and renal injury, especially in patients
with older age and comorbidities (diabetes mellitus,
hypertension, and heart failure) [3–5]. According to
disease progression, patients may be roughly divided
into two groups; asymptomatic or mild cases that usually

recover and severe cases (approximately 15%) that
develop multi organ failure, primarily respiratory failure,
requiring intensive care unit (ICU) admission [4, 5]. An
efficient immune response against SARS-CoV-2 may be
considered fundamental for the resolution of COVID-19.
However, some studies have shown a significant
relationship between the disease severity and the levels of
proinflammatory cytokines and subsets of immune cells
[6,7]. It has been suggested that during the response to
SARS-CoV-2, the immune dysregulation and the high level
of proinflammatory cytokines could be the main cause
of tissue injury. Eventually, the exact pathophysiologic
mechanism of COVID-19 remains still largely unknown.
2.The origin and structural features of SARS-CoV2
CoVs belong to big family Coronaviridae which consists
of two subfamilies: Orthocoronavirinae and Torovirinae.
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On the basis of genomic and phylogenetic relationship,
the subfamily Orthocoronavirinae is classified into
four genera: alphacoronaviruses, betacoronaviruses,
gammacoronaviruses, and deltacoronaviruses [8]. The
alphacoronaviruses and betacoronaviruses tend to infect
mammals and cause respiratory and gastrointestinal
infection in humans like SARS coronavirus (SARS-CoV),
MERS coronavirus (MERS-CoV), and SARS-CoV-2,
while gammacoranaviruses and deltacoronaviruses have
the ability to infect birds in addition to mammals [2,9].
The betacoronaviruses comprise of SARS-CoV, MERSCoV, Human coronaviruses (HCoVs), Bat-SARS-like (SL)
coronaviruses, and lastly identified SARS-CoV-2. SARSCov-2 possesses nonsegmented, single-stranded positivesense RNA (+ssRNA) with 5’-cap structure and 3’-poly-A
tail which is a typical genomic structure of CoVs [10]. The
genome analyses have revealed that the genome sequence
of SARS-CoV-2 is 96% and 79.5% identical to the bat
coronavirus termed BatCoV RaTG13, and SARS-CoV,
respectively [2].Therefore, the bat has been suggested as
a natural host of SARS-CoV-2 and the transmission route
of SARS-CoV-2 could be through unknown intermediate
hosts. The genetic analyses of SARS-CoV-2 genomes from
103 Chinese patients demonstrated that this virus has been
evolved into two main types; L type(~ 70%) and S type(~
30 %). L type is more aggressive and infectious than S type
which is the ancestral version[11].
The genome of CoV contains six major open reading
frames (OFRs) and numerous accessory genes. First OFRs
(OFR1a/b), which encompasses the two-third of viral
RNA, encode two large proteins of CoVs, polyprotein 1a
(pp1a) and pp1ab. These polyproteins are divided into
16 nonstructural proteins (nsps), responsible for viral
RNA replication and transcription, by virally encoded
chymotrypsin-like protease (3CLpro) or main protease
(Mpro) and papain-like protease (PLpro) [12,13]. The
remaining OFRs on the one-third of the genome encode
major structural proteins, including spike (S), envelope
(E), membrane (M), and nucleocapsid (N) proteins, all of
which are crucial for the viral infectivity as seen in Figure.
CoVs possess a lipid bilayer envelope with S, M, and E
proteins [14,15]. The N protein is composed of an amino
(N)-terminal (NT) domain and acarboxy (C)-terminal
cytoplasmic tail (CT) domain and located in the core of
the viral particle. Both domains bind to viral RNA to form
the helical nucleocapsid [16,17]. Besides, SARS-CoV N
protein acts as an antagonist to the interferon pathway by
regulating the signaling and synthesis of type I interferon
(IFN), which is one of the most important response in the
innate immunity to viral infection [18]. The M protein is
the most abundant component of the viral envelope. The
M protein contains a glycosylated NT ectodomain, three
transmembrane (TM) domains, and a CT domain that

binds to the nucleocapsid. The M protein gives the shape
of the virus and promotes the membrane curvature and
the virus assembly by interacting with the S protein and
the ribonucleoprotein [14,19,20]. The E protein is a small
integral membrane protein, including an NT ectodomain,
a TM domain, and a CT endodomain. The E protein
facilitates the assembly, the budding, and the envelope
formation as well as the M protein [21]. Moreover, the E
protein has an ion-channel activity, contributing factor
of the inflammasome activation. The animal study has
shown that blocking the ion channel activity of SARSCoV E protein by deletion of associated genes leads to the
reduction of the edema and the level of inflammasomeactivated interleukin (IL)-1β, IL-6, and tumor necrosis
factor (TNF) all of which have an important role in the
progression of ARDS [22].
The S glycoproteins on the surface of CoVs are the
receptor binding proteins which are responsible for the
attachment to host cells, viral-host cell membrane fusion,
and the internalization of the virus [14]. S genome of
SARS-CoV-2 has less than 75% identical sequence with
previously known SARS-CoVs except for RaTG13 which
of S genome is 93.1% identical with SARS-CoV-2 [2].
Besides, another genome analyses have elucidated that
the sequence identity of S protein between SARS-CoV-2
and SARS-CoV is %76 and most variation has been seen
at the N terminus [23,24].The S glycoprotein consists of
two domains: S1 domain which includes receptor-binding
domain (RBD), interacting with angiotensin-converting
enzyme 2 (ACE2) on the human host cells as SARS-CoV,
and S2 domain which mediates virus-cell membrane
fusion and viral entry [2,25]. The S2 domain comprises
of three parts; a large ectodomain; a single TM domain,
and a CT domain [26]. The sequence of RBD from SARSCoV and SARS-CoV-2 exhibits 73.5% identity [24]. The
current study has indicated that the RBD of SARS-CoV-2
has lower affinity to ACE2 than the RBD of SARS-CoV
[27]. However the result of the another study revealed
that SARS-CoV2- S protein binds ACE2 with higher
affinity than SARS-CoV [28]. After attachment of SARSCoV-2 with S protein to ACE2 on the host cells, S protein
is cleaved by host cell proteases to reveal the S2 domain
for viral-host membrane fusion and viral entry which is
coupled with TNF-α production [10, 29, 30].
3. The immune response and cytokine storm in
COVID-19
The effective antiviral responses of the host innate and
adaptive immunity, including the production of various
proinflammatory cytokines, the activation of T cells, CD4
and CD8+ T cells, are essential for controlling the viral
replication, limiting the spread of virus, inflammation and
cleaning the infected cells [31,32]. Nevertheless, the tissue
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Figure. The schematic image of coronavirus (CoV). CoVs, enveloped virus, possess nonsegmented, positive (+) ssRNA genome with
structural proteins: Spike (S) glycoprotein, membrane (M) protein, nucleocapsid (N) protein, and envelope (E) protein. SARS-CoV-2
S protein attaches to angiotensin-converting enzyme 2 (ACE2) receptor on the host cell to entry. After the attachment, host endosomal
proteases mediate the virus membrane-endosome fusion for the release of the viral genome. Chloroquine (CQ) and hydroxycloroquine
(HCQ) block the virus-receptor binding and virus-endosome fusion. Besides CQ, HCQ, and intravenous immunoglobulin (IVIg) inhibit
the production of cytokines in macrophages and the antigen presentation in dendritic cells. In COVID-19, the count of neutrophils
and leukosytes increase whereas the total count of lymphocytes CD4+ T cells, CD+8 T cells, regulatory T (T reg) cells, memory T
cells, natural killer cells, and B cells decrease. Another beneficial effect of CQ and HCQ is increasing the activity of Treg. The aberrant
proinflammatory cytokine production is observed in COVID-19. Several immunomodulatory therapies including interleukin (IL)-6
antagonists, granulocyte colony-stimulating factor (GM-CSF) inhibitor, IL-1 antagonists, IL-17 antagonists, and antitumor necrosis
factor (TNF) agents might be used for this cytokine storm to resolve and limit the further inflammation and tissue damage (The yellow
arrow indicates a decrease in the number of cells; the blue arrow indicates and increase in the number of cells).
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injury caused by the virus could induce the exaggerated
production of proinflammatory cytokines, the recruitment
of proinflammatory macrophages and granulocytes. This
results in the cytokine storm (CS) termed as a macrophage
activation syndrome (MAS) or secondary hemophagocytic
lymphohistiocytosis (sHLH), thus leading to further
tissue damage [33–35]. Data obtained from SARS-CoV-2
infected patients have shown that severe cases may be
characterized by a cytokine storm inexorably progressing
to ARDS [36–38]. Several features of COVID-19, such
as the cytokine profile, serological markers, and clinical
symptoms, resemble sHLH most commonly triggered by
viral infection [6, 34]. Furthermore, another important
evidence is that the severity of COVID-19 is related to
the level of the proinflammatory cytokines and subsets of
immune cells [6,39].
COVID-19 possesses different levels of various
cytokines and chemokines through the mild to severe
stage of the disease. In SARS-CoV-2 infected patients,
the retrospective analysis has demonstrated that initial
plasma levels of IL-1β, IL-1RA, IL-7, IL-8, IL-10, IFN-ɣ,
monocyte chemoattractant peptide (MCP)-1, macrophage
inflammatory protein (MIP)-1A, MIP-1B, granulocytecolonystimulating factor (G-CSF), and tumor necrosis
factor-alpha (TNF-α) are increased in patients with
COVID-19. The further analysis has shown that the
plasma concentrations of IL-2, IL-7, IL-17, IL-10, MCP1, MIP-1A, and TNF-α in ICU patients are higher than
non-ICU patients [36]. Moreover, the plasma levels of
IL-2, IL-6, IL-8, IL-10, and TNF-α, observed in severe
infection, are prominently greater than those in nonsevere
infection [37]. Few retrospective studies have revealed
that the lung injury reported with Murray score is strongly
associated with the level of IL-1α, IL-1ra, IL-2, IL-7, IL10, IL-17, IFN-ɣ, inducible interferon protein (IP)-10,
G-CSF, and MCP-3 and these cytokines and chemokines
excluding MCP-3 are positively related to SARS-CoV-2
viral load2[7]. The plasma level of IL-6, considered as a
significant cytokine contributing to MAS, increases both
in mild and severe patient groups of COVID-19: severe
patients have a significantly higher level of IL-6 than mild
or nonsevere patients [6,37,38,40]. Furthermore, based
on the assessment of pulmonary infiltration in patients
with ARDS, the large area of lung injury (≥50%) is closely
correlated with the increased level of IL-6 and the subgroup
of lymphocytes in the peripheral blood [41].
During the infection, both innate and adaptive
immune cells synergistically participate in the anti-viral
response [42].The important increment in the number of
neutrophils, leukocytes, and the neutrophil-lymphocyteratio (NLR) has been observed in severe COVID-19

compared to mild cases. The prominent lymphopenia,
indicating an impairment of immune system, develops in
most COVID-19 patients especially in severe ones [4,37].
Therefore, it seems that neutrophils and leukocytes might
reinforce the CS other than lymphocytes in COVID-19.
The level of lymphocytes and subsets of T cells which play
a significant role in the balancing of immune response
varies according to the type of the virus due to possible
viral pathologic mechanism. Previous investigations
have elicited that the total count of lymphocytes and
the subset of T cells are reduced in patients with SARSCoV infection [43,44]. Data from recent studies have
suggested that SARS-CoV-2 infection can lead to immune
dysregulation through affecting the subsets of T cells. The
significant alleviation of T cells is observed in COVID-19
and more pronounced in severe cases. In patients with
COVID-19, the level of helper T cells (CD3+, CD4+)
and cytotoxic suppressor T cells (CD3+, CD8+), and
regulatory T cells are below normal level while helper
T cells and regulatory T cells in severe patients are
remarkably lower than nonsevere patients. Regulatory T
cells are responsible for the maintenance of the immune
homeostasis with suppressing the activation, proliferation,
and proinflammatory function of most lymphocytes
including CD+4 T cells, CD+8 T cells, NK cells, and B
cells [45,46]. Furthermore, the percentage of naïve helper
T cells amplifies while the percentage of memory helper
T cells and CD28+ cytotoxic suppressor T cells decreases
in severe COVID-19 [6, 37]. The equilibrium between
the naïve T cells and memory T cells is fundamental
for mediating the efficient immune response [47]. In
addition to T cells, the reduction of B cells and NK cells
are seen in COVID-19. Another important result is the
confirmed strong relationship between inflammatory
markers, including ESR, CRP and IL-6 and the subset of
lymphocytes [39]. However, previously it has been shown
that there is no significant correlation between IL-6 and
subsets of lymphocytes [6]. Although these reports have
indicated that CD+4/CD+8 T cell ratio in SARS-CoV-2
infection is similar to the healthy group, the increase
in this ratio and the decline of CD+8 T cells and B cells
are considered as a poor predictor for the assessment of
post-treatment clinical follow-up [6, 39]. Taken together,
these results indicate that SARS-CoV-2 is responsible for
an immune dysregulation with the induction of aberrant
cytokine and chemokine response, alteration in level of
the subgroup of lymphocytes all of which might result in
cytokine storm and further tissue damage.
Excessive inflammatory response with features of
cytokine storm cause severe disease course and worsens
the prognosis in COVID-19. Undoubtedly, definitive and

Liu Y, Zhang C, Huang F, Yang Y, Wang F et al. (2020). 2019–novel coronavirus (2019-nCoV) infections trigger an exaggerated
cytokine response aggravating lung injury [online]. Website http://chinaxiv.org/abs/202002.00018 [accessed 01 April 2020].
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most effective treatments for COVID-19 drugs would
be the antiviral agents that directly target SARS-CoV-2.
Considering the lack of proven antiviral agents and
hyperinflammation caused by virus, antiinflammatory
drugs used in daily rheumatology practice may constitute
possible treatment options in treatment of COVID-19.
Following antiinflammatory treatments are potential
candidates for COVID-19 with their preclinical or limited
clinical evidence.
4. Potential antiinflammatory treatments used in
Rheumatology for COVID-19
4.1. Corticosteroids
Systemic corticosteroids have broad-spectrum actions
on the immune system that may suppress the exuberant
systemic inflammatory response that occurs in
ARDS. Severe multi-source systemic inflammation is
associated with adverse outcomes, so one may think that
corticosteroids may of benefit with their broad spectrum
immunosuppressive effects. However, evidence has shown
that use of corticosteroids delayed viral clearance in SARS
and MERS infections, similarly they increased secondary
infection rates, mortality and complications of steroid
therapy in survivors of influenza pneumonitis [48]. In a
randomized controlled trial that included 16 non-ICU
SARS patients, “early” (<7 days of illness) hydrocortisone
therapy was associated with a higher subsequent plasma
viral load. Therefore, corticosteroids should not be used
early phases of disease unless there is a clear indication for
their use [49]. In SARS infection, some patients showed
severe inflammatory features despite reductions in viral
load with subsequent seroconversion, suggestive of
exuberant immune response independent of viral load [50].
In two small observational study, use of corticosteroids did
not show a survival benefit in COVID-19 patients even
increased mortality rates when used in high doses [51–53].
Moreover, corticosteroid use was prolonged SARS-CoV-2
RNA shedding as observed in SARS and MERS infections
[54]. In the light of preliminary data, corticosteroids are
more likely to function on inflammation-mediated lung
injury and interstitial fibrosis at late-stage of ARDS [52].
However, the dose, duration, and timing of corticosteroids
must be individualized considering risk-benefit ratio,
until results of ongoing well-designed prospective cohort
studies obtained. At present, several studies are registered
to assess the efficacy of corticosteroids in COVID-19.
4.2. Chloroquine and hydroxychloroquine
Chloroquine (CQ) and hydroxychloroquine (HCQ) are
4-aminoquinoline derivatives that are approved by the U.S.
Food and Drug Administration (FDA) for the treatment
of malaria, systemic lupus erythematosus, rheumatoid
arthritis (RA) and decades of experience in use of these
disorders. They are also used in Q fever and porphyria
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cutanea tarda. HCQ has a better side effect profile than CQ
and is strongly recommended for the long-term treatment
of lupus unless the occurrence of a severe side effect. HCQ
does not increase the risk of infections and has lipidlowering, antithrombotic and antineoplastic properties
[55]. In adult rheumatic diseases, the recommended dosage
is 200 to 400 mg (155 to 310 mg base) with a cut off of 6.5
mg/kg/daily, is usually well-tolerated. The most dreaded
complication is retinal toxicity which rarely occurs in long
term use (five or more years). Elders with kidney failure or
tamoxifen users have an increased risk of retinal toxicity.
CQ and HCQ may prolong QT interval which does not
require routine ECG monitorization in recommended
doses. At higher doses, these drugs have a potential risk
of fatal arrhythmia or if combined with QT prolonging
medications as well as those with cardiac diseases [56].
Other acute notable toxicities of 4-aminoquinoline
derivatives are allergic reactions and neuropsychiatric
events [57]. Very rarely they may cause cardiomyopathy
which is thought to occur due to lysosomal accumulation
with their chronic use [58].
Oral absorption of CQ and HCQ are very good and are
excreted primarily by urine. The half-lives of CQ and HCQ
are prolonged, ranging between 40 and 50 days and have
a large volume of distribution, which allows for sustained
sequestration in the tissues. Tissue concentrations may
differ with being highest in the lung tissue about 30-fold
of plasma concentrations as shown in animal models [59].
It has been known that CQ and HCQ have antiviral
activity including hepatitis B, HIV, H1N1 and Zika virus
[60]. Antiviral activity of HCQ was first observed in HIV
and the hepatitis B infections in the early 1980s. Small
studies showed its favorable efficacy in combination
regimens of HBV, HCV and HIV infections. CQ and
HCQ are thought to exert antiviral activity via multiple
mechanisms. First, these agents interfere with glycosylation
and proteolytic maturation of proteins. By interfering with
terminal glycosylation of ACE2, the cellular receptor for
S protein, both agents block virus-receptor binding and
cell entry [61, 62]. Second, CQ and HCQ both are weak
bases and concentrated in acidic, low-pH organelles, such
as endosomes, Golgi vesicles, and lysosomes, increasing
their pH [61]. Endosomal acidification is required for
the activation of endosomal proteases responsible for the
initiation of coronavirus/endosome fusion that releases
viral particles into the infected cells [63]. Therefore,
CQ and HCQ inhibit viral release into the host cell by
blocking endosomal acidification. Third, HCQ inhibits
protein glycosylation and proteolytic maturation of
viral proteins. Budding of the SARS-CoV occurs in the
Golgi apparatus and results in the incorporation of the
envelope spike glycoprotein into the virion [64]. Studies
have shown a resulting accumulation of noninfective viral
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particles of HIV, or an inability of viral particles to bud
out of the host cell, reducing spread of infection. Finally,
antimalarial drugs act as protecting hemoglobin against
invasion by malaria parasites with their effects on heme
metabolism. There is abnormal heme metabolism in
COVID-19 patients. Chloroquine phosphate competes
with the porphyrin and binds to the viral protein, thereby
inhibits the viral protein’s attack on heme or binding to
the porphyrin. According to a study, CQ could prevent
ORF1ab, ORF3a, and ORF10 to attack the heme to form
the porphyrin and inhibit the binding of ORF8 and surface
glycoproteins to porphyrins to a certain extent3.
In rheumatic diseases, the exact mechanism of action
of HCQ and effects on the immune system are largely
unknown. However, beside interfering with lysosomal
activity and autophagy as mentioned above, CQ and
HCQ interact with membrane stability and alter signaling
pathways and transcriptional activity, which can result
in inhibition of cytokine production and modulation
of certain costimulatory molecules. Both drugs inhibit
antigen presentation in dendritic cells, cytokine production
in macrophages, and calcium, Toll-like receptor (TLR) and
cGAS-STING signaling in B, T and other immune cells [55,
65]. The major proposed immunomodulatory mechanisms
of CQ and HCQ are the following: inhibition of cytokine
production and release by T cells: IL-1, IL-2, IL-6, and
IL-18, TNF-α and IFN-γ, reduced levels of chemokines,
CCL2 and CXCL10, inhibition of micro-RNA expression,
decreased TH17-related cytokines, increased in Treg
activity and upregulated levels of IFN-α and IL-2 and IL10, inhibition of cytotoxic T cell and self-reactive CD4+
lymphocyte activities, decreased DNA, RNA and protein
synthesis in thymocytes [55]. Antimalarials have ironbinding and hydroxyl radical scavenging actions which
may of benefit considering disrupted heme metabolism
and oxidative stress [66].
A strong antiviral activity of CQ by using SARSCoV-2–infected vero cells has been documented [67]. In
a physiologically based pharmacokinetic models (PBPK)
for each drug, HCQ showed five-fold more potency than
CQ in vitro [68]. In both studies, antiviral activity is dosedependent and can be achieved with use of routine safe
dosages.
Although several in vitro studies report antiviral
activity of CQ and HCQ against SARS-CoV-2, in vivo
data are promising but have considerable limitations. An
expert consensus group in China suggested that CQ may
improve lung involvement evaluated at imaging with a
shortening of the disease course [69]. In another highly
debated open-label, nonrandomized, controlled trial, a

small number of patients with COVID-19 were treated
with HCQ. Nasal SARS-CoV-2 carriage was found to be
lower on sixth day following HCQ treatment as compared
to non-treated patients [70]. A recent, multicenter, openlabel, randomized controlled trial from China, did not find
SARS-CoV-2 negative conversion rates between high dose
HCQ and standard of care in 150 hospitalized patients,
with reporting more rapid resolution of symptoms,
normalization of CRP and lymphopenia, however outcome
data on ICU need and mortality was not reported here[71].
In another study comprising 181 hypoxic pneumonia
patients from France, HCQ did not avert ICU admission
or mortality [72].The dilemma on clinical utility of CQ
and HCQ in COVID-19 will be solved by well-designed
clinical trials in near future.
In several countries, despite the weakness of clinical
studies, based on strong preclinic scientific rationale and
multimodal antiviral and immunomodulatory actions,
CQ and HCQ are currently recommended for the
treatment of COVID-19. Optimal dosing is uncertain and
there are several dosing regimens (400 mg to as high as
1200 mg daily) as is the treatment durations (5–10 days).
HCQ was found to be more potent than CQ in vitro and
better tolerated. Based on PBPK models, a loading dose,
400 mg twice a day (BID), of HCQ is given orally, followed
by a maintenance dose of 200 mg BID for 4 days is the
most commonly recommended strategy for SARS-CoV-2
infection, as it reached three times greater potency of
CQ when given 500 mg twice daily for 5 days in advance
[68]. All HCQ recommended doses for COVID-19 are
above the routine doses used in rheumatic diseases, hence
potential adverse events could be experienced also in this
brief standing treatment.
In 2005 Vincent et al. reported that CQ has strong
antiviral effects on SARS-CoV-1 infection of primate
cells with the use of drug either before or after exposure
to the virus, suggesting both prophylactic and therapeutic
use [61]. Animal models have shown that prophylactic
use of CQ may have an additional survival benefit in
enteroviral infections [73]. However, there is still no
robust evidence for the use of CQ or HCQ for pre- or
postexposure prophylaxis of COVID-19. There are several
trials underway to evaluate the efficacy of CQ or HCQ in
the prophylaxis of high-risk individuals (NCT04303507,
NCT04318444).
4.3. Intravenous immunoglobulin (IVIg)
IVIg is a blood product containing polyclonal
immunoglobulin G isolated and pooled from healthy
donors used to treat Immune Thrombocytopenic
Purpura (ITP), Kawasaki disease and various

Liu W, Li H (2020). COVID-19 Disease: ORF8 and Surface Glycoprotein Inhibit Heme Metabolism by Binding to Porphyrin
[online]. Website https://chemrxiv.org/articles/COVID19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_
by_Binding_to_Porphyrin/11938173/3 [accessed 04 April 2020].
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inflammatory neurologic and myositis syndromes.
It has immunomodulatory functions with unknown
mechanism of action. One of the proposed mechanisms
is the interaction of IgG-Fc with Fc gamma receptors
located on almost all immune cells, resulting in pleiotropic
functional consequences including the expansion of
regulatory T cell population, phagocytosis, antibodydependent cellular cytotoxicity (ADCC), immune cell
differentiation and maturation, apoptosis, expression of
proinflammatory cytokines, and antigen-presentation
[74]. Previous studies on SARS and MERS, found that
IVIg therapy was effective thus proposing high-dose IVIg
as an option for severe COVID-19 patients [75]. There are
a few COVID-19 cases which reported efficacy of high
dose IVIg[76]. However, its high cost and limited supply
restrict its general use. Inferred from rheumatic diseases,
COVID-19 patients with pregnancy, secondary infections,
marked thrombocytopenia, muscular, myocardial and
neurologic manifestations would be better candidates for
IVIg treatment. There are several studies already registered
for its use in COVID-19.
4.4. IL-6 antagonists
IL-6 receptors ubiquitously expressed in almost all immune
cells, and IL-6 acts as a master player inducing proliferation
and differentiation of immune cells. In healthy individuals,
the IL-6 levels in circulation are extremely low and are in
the range of 1–5 pg/mL, marked elevations reported in
many inflammatory conditions including cytokine release
syndrome [77]. Several therapeutic agents have been
developed inhibiting the cytokine itself, the signaling via
the IL-6 receptor, or its postreceptor downstream signaling
pathways (JAK/STAT). Tocilizumab, sarilumab, siltuximab
are IL-6 antagonists with different pharmacologic
properties. Tocilizumab is approved for the treatment
of RA, juvenile idiopathic arthritis, giant cell arteritis,
cytokine release syndrome, and idiopathic multicentric
Castleman’s disease (iMCD), whereas siltuximab received
approval for iMCD and sarilumab for RA only [78].
COVID-19 patients have high plasma IL-6 levels,
especially those with more severe disease presentation [37].
IL-6 production can be stimulated by SARS-CoV-2 itself
or by stimulation of other immune cells [79]. Indeed, it has
been shown that during COVID-19, CD4+T lymphocytes
are rapidly activated to differentiate into pathogenic Th1
cells, generating GM-CSF and other proinflammatory
cytokines, which further induced activation of monocytes
with high expression of IL-6 [80]. In clinical view, there
is striking correlation between serum IL-6 levels and

SARS-CoV-2 RNAaemia, which strongly indicates worse
outcome4. Besides the cytokine storm, recent studies in
experimentally infected animals suggest a crucial role
for virus-induced immunopathological events in causing
fatal pneumonia after coronavirus infections [81]. Hence,
blocking IL-6 would potentially reduce the detrimental
immune response caused by SARS-CoV-2.
As are the other COVID-19 treatments, there is no
robust evidence to routinely suggest IL-6 antagonists. A
small clinical trial in China examined the effectiveness
of tocilizumab in 21 patients who met the criteria for
severe or critical COVID-19, including respiratory failure,
requiring mechanical ventilation, shock, or admission
to the ICU with multiple organ failures. Tocilizumab
improved hypoxemia, fever, lymphopenia, CRP, and
lung infiltration in most of the patients treated, without
serious adverse events5. Recently, the favorable outcome of
a patient with limited cutaneous systemic sclerosis under
treatment with tocilizumab was reported [82].
Since there is an urgent need for the severe COVID-19
treatments, based on these limited data, tocilizumab is
included in the treatment algorithms of many countries.
The dose and timing for infusions are not determined
yet. Numerous studies are ongoing to assess the efficacy
of tocilizumab, sarilumab, and siltixumab in several
countries. Current practice is to give tocilizumab 4–8 mg/
kg (maximum 800 mg) as single infusion. After careful
evaluation of disease severity and response to initial
treatment a repeat infusion can be administered at the
same dose after 12–24 h. IL-6 antagonists increase the risk
of infections, therefore must be used in severe patients
and at the end of the high viral load phase of COVID-19,
along with antiviral treatments [75]. There are other side
effects including intestinal perforation and opportunistic
infections. Therefore, it is prudent to monitor patients for
potential side effects.
4.5. Janus kinase (JAK) inhibitors
JAK inhibitors are potent inhibitors of one or more of the
JAK family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby
interfering with the JAK-STAT signaling pathway. The
JAK/STAT pathway mediates the effect of many different
molecules, including interleukins (IL-2, IL-3, IL-4, IL-5,
IL-6, IL-7, IL-9, IL-10, IL-12, IL-15, IL-21, IL-23), IFN-(α,
β, γ) and growth factors (GM-CSF, TGF-β, erythropoietin
and thrombopoietin) [83]. JAK inhibitors are currently
approved for the treatment of RA and psoriatic arthritis and
their use in other inflammatory disorders are continuously
growing [84]. Many proinflammatory cytokines involved

Chen X, Zhao B, Qu Y, Chen Y, Xiong J, et al. (2020). Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated
with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients [online]. Website https://www.medrxiv.org/
content/10.1101/2020.02.29.20029520v1 [accessed 06 April 2020].
4

Xu X, Han M, Li T, Sun W, Wang D, et al. (2020). Effective treatment of severe COVID-19 patients with tocilizumab [online]. Website
https://www.ser.es/wp-content/uploads/2020/03/TCZ-and-COVID-19.pdf [accessed 06 April 2020].
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in cytokine storm of COVID-19 might be inhibited by JAK
inhibitors.
Besides above mentioned common properties of
JAK inhibitors, baricitinib may block AP-2-associated
protein kinase 1 (AAK1) and cyclin G-associated
kinase (GAK) which are host kinases that regulate viral
endocytosis, according to an artificial intelligence search
of viral characteristics of SARS-CoV-2. This effect is only
restricted to baricitinib among other JAK inhibitors and
it may block viral entry and assembly of virus particles
into pneumocytes in therapeutic doses used in RA [85].
However, these hypothetical views merit further evidence
for clinical use both for cytokine storm and COVID-19.
Currently, baricitinib (NCT04320277, NCT04340232,
NCT04321993),
tofacitinib
(NCT04332042)
and
ruxolitinib (NCT04331665) studies are ongoing.
4.6. Anakinra
Nod-like receptor family pyrin domain-containing 3
(NLRP3) is a critical inflammasome in acute protection
of the body against a wide variety of noxious stimuli,
including RNA viruses [86]. NLRP3 activates caspase-1,
a molecule responsible for the activation and exuberant
release of IL-1β and IL-18. Previously SARS-CoV has
been shown to induce NLRP3 by its ion channel-forming
M protein and ORF8b [87]. It has been shown that SARSCoV-2 induces many cytokines including IL-1 family
[36, 37]. IL-1 family are pleiotropic cytokines, have roles
in inflammation, hematopoiesis, and fibrosis. IL-1β and
TNF-α promote vascular permeability and leakage. Both
IL-1β and IL-18 fuel cytokine storm and MAS and IL-1
cytokines (except IL-18) can be successfully inhibited by
anakinra [88].
Anakinra is a recombinant antagonist of human
IL-1 and approved for the treatment of RA and certain
autoinflammatory disorders with recommended doses of
1–2 mg/kg/day with a maximum daily dose of 8 mg/kg6
[89]. In terms of sepsis and MAS, a previous, highly cited
phase III trial, anakinra did not improve 28-day survival
rate in sepsis patients and terminated early [90]. However,
reanalysis of data from this trial suggested significant
improvement in survival in patients with hepatobiliary
dysfunction and disseminated intravascular coagulation
(DIC) [91]. Anakinra was administered intravenously at
2 mg/kg/hr for 72 h continuously in this study without
safety concerns. This dose is extremely higher than those
used in rheumatology routine which warrants careful
monitoring. There are several anakinra studies registered
for COVID-19, testing 100 mg daily subcutaneous
injection for 28 days to 400–600 mg/day intravenous for
5–7 days (NCT04339712, NCT04330638).

4.7. Colchicine
Colchicine has been approved for gout and familial
Mediterranean fever. In recent years, colchicine has
attracted attention in the management of cardiovascular
diseases by suppressing their inflammatory component
[92]. Its mechanism of action is thought to be the inhibition
of tubulin polymerization and microtubule generation
and, possibly, effects on cellular adhesion molecules,
inflammatory chemokines, and the inflammasome.
Colchicine may inhibit activation of NLRP3 inflammasome
and additionally may inhibit directly the synthesis of
TNF-α and IL-6 [93]. Trials investigating the efficacy of
conventional therapeutic doses of colchicine have been
registered for the treatment of COVID-19 (NCT04322682,
NCT04328480, NCT04326790).
4.8. Anti-TNF agents
TNF-α is one of the most potent proinflammatory
cytokines with broad spectrum of actions. Marked
elevations reported in many inflammatory conditions
including cytokine release syndrome. Serum TNF-α levels
found elevated in COVID-19 patients with being more
pronounced in more severe patients [36]. SARS-CoV
viral spike protein is able to modulate TNF-α-converting
enzyme (TACE)-dependent shedding of the ACE2
ectodomain, required for the viral entry which is coupled to
TNF-α production [94]. Therefore, it is hypothesized that
the use of TNF inhibitors might be effective in blocking
viral entry and detrimental effects of exuberant TNF-α, as
shown in preclinical studies on severe respiratory syncytial
virus and influenza infections [95]. Anti-TNFs enhance
the risk of bacterial, viral and fungal infections. Therefore,
their use in COVID-19 must be supported with preclinical
studies.
4.9. Anti-IL-17 antagonists
One of the cytokines found abundant in COVID-19
patients is IL-17 and found associated with severe
lung inflammation [36]. IL-17 has wide-ranging
proinflammatory effects on induction of cytokines; IL1β, IL-6, TNF-α; growth factors, G-CSF; chemokines; and
matrix metalloproteinases. In a mouse model, it was found
that H1N1 cause acute lung injury in an IL-17-dependent
manner. It has been postulated that blocking this cytokine
may be effective in reducing SARS-CoV-2 related organ
damage [96].
4.10. Mavrilimumab
As mentioned, GM-CSF is one of the key molecules
involved in cytokine storm which is excessively released
in COVID-19 patients [80]. Blockage of this growth
factor may halt immunopathology caused by virus.
Mavrilimumab is a GM-CSF inhibitor developed for the

FDA (2001). Kineret® (anakinra) for injection, for subcutaneous use: highlights of prescribıng information [online]. Website https://
www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf [accessed 10 April 2020].
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refractory RA [97] and a new trial is investigating its
efficacy in COVID-19 (NCT04337216).
4.11. Mycophenolate mofetil (MMF)
MMF is widely used for the treatment of severe
manifestations of connective tissue disorders and vasculitis
syndromes. Mycophenolate exhibited strong antiviral
effects on SARS-CoV and MERS-CoV as demonstrated
in vitro studies, with its interaction with viral proteases
[98]. A small clinical study reported efficacy of MMF in
combination with IFN-β on MERS patients [99]. However,
considering strong immunosuppressant effects of MMF, it
is likely to cause more harm than benefit in COVID-19
patients.
4.12. Nonsteroidal antiinflammatory drugs (NSAIDs)
An association between ibuprofen and worse outcome
in COVID-19 patients was speculated, with very weak
evidence [100]. Another NSAID, indomethacin, reported
to have direct antiviral effect on SARS-CoV by interfering
with viral RNA synthesis, independent of cyclooxygenase
inhibition in an in vitro study. A registered trial, currently
recruiting patients to determine efficacy of naproxen
for its potential interaction with viral nucleoproteins
(NCT04325633). Therefore, although evidence is limited,
indomethacin or naproxen could be preferred over other
NSAIDs when indicated [101].

5. Conclusion
Excessive inflammatory response with features of cytokine
storm cause severe disease course and worsens the
prognosis in COVID-19. Undoubtedly, drugs that directly
target SARS-CoV-2 would be the most effective treatments
for COVID-19. There are hundreds of trials ongoing to
find effective treatments for COVID-19 both targeting
virus and consequent hyperinflammation including
newly developed agents on phase studies or drugs that are
approved for other indications. Until an effective treatment
is found, drugs that are used in daily rheumatology practice
may constitute potential treatment options in COVID-19
patients not only by their antiinflammatory effects but also
with some of their inherent antiviral properties. Hence,
inclusion of rheumatologists/ immunologists into COVID
teams would improve patient outcomes.
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